Related Experiment Video
Updated: Jan 18, 2026
A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model
Published on: February 28, 2018
A Prebiotic-Supplemented Formula Improves Gut Microbiota and Intestinal Inflammatory Microenvironment in Patients
Sijia Meng1, Chen Liu1, Keming Zhang2
1Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China.
Background:
Colorectal cancer is preventable, and patients with colorectal adenomas are at high risk of colorectal cancer.
Objectives:
This study aimed to evaluate the effects of a complex prebiotic formulation on the gut microbiota and inflammation levels in patients with colorectal adenoma.
Methods:
A randomized double-blind placebo-controlled trial assigned patients with adenomatous polyps to either the prebiotic intervention group (N = 51) or the placebo control group (N = 49). Blood and stool samples were collected at baseline and week 12; mixed-effects models were used to analyze the impact of the prebiotic on gut microbiota and inflammatory markers.
Results:
Both groups showed an increase in Bacteroidetes abundance over 12 wk, but the increase was smaller in the intervention group [β = -5.507; 95% confidence interval (CI): -11.390, 0.375; P = 0.066]. Unidentified Ruminococcaceae increased in the intervention group (β = 2.072; 95% CI: -0.130, 4.274; P = 0.065), but declined in the control group. A significant increase in interleukin-10 concentrations was observed in the intervention group (β = 0.778; 95% CI: 0.132, 1.425; P = 0.019), in contrast to a downward trend in the control group. Notably, baseline tumor necrosis factor-α concentrations appeared to modify the intervention's microbial effects. Specifically, for each 1 pg/mL increase, the intervention was associated with increased Actinobacteria (β = 0.624; 95% CI: 0.100, 1.148; P-interaction = 0.020), Bifidobacteriaceae (β = 0.608; 95% CI: 0.114, 1.103; P-interaction = 0.017), and Bifidobacterium (β = 0.608; 95% CI: 0.114, 1.103; P-interaction = 0.017). However, these associations did not remain statistically significant after false discovery rate adjustment.
Conclusions:
The prebiotic intervention effectively increased the abundance of beneficial bacteria, while simultaneously reducing inflammatory levels in individuals with colorectal adenoma. This trial was registered at the Chinese Clinical Trial Registry as ChiCTR2100046390.
More Related Videos
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...